Customize your JAMA Network experience by selecting one or more topics from the list below.
In the JAMA Insights article titled “Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,” published July 20, 2021,1 there was an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation of PCSK-9 mRNA. This article was corrected online.
Incorrect Classification of Pharmaceutical Agent. JAMA. 2021;326(9):873. doi:10.1001/jama.2021.14278
Coronavirus Resource Center
Create a personal account or sign in to: